Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors.

Bai JP, Lesko LJ, Burckart GJ.

Pharmacotherapy. 2010 Feb;30(2):195-209. doi: 10.1592/phco.30.2.195.

PMID:
20099993
2.
3.

Calcineurin inhibitor nephrotoxicity.

Naesens M, Kuypers DR, Sarwal M.

Clin J Am Soc Nephrol. 2009 Feb;4(2):481-508. doi: 10.2215/CJN.04800908. Review.

4.

Calcineurin inhibitors in renal transplantation: what is the best option?

Tanabe K.

Drugs. 2003;63(15):1535-48. Review. Erratum in: Drugs. 2003;63(20):2234.

PMID:
12887261
5.

Calcineurin inhibitor-induced renal allograft nephrotoxicity.

Krejci K, Tichy T, Bachleda P, Zadrazil J.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Dec;154(4):297-306. Review.

6.

Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors.

Utecht KN, Hiles JJ, Kolesar J.

Am J Health Syst Pharm. 2006 Dec 1;63(23):2340-8. Review.

PMID:
17106006
8.

Hypertensinogenic mechanism of the calcineurin inhibitors.

Curtis JJ.

Curr Hypertens Rep. 2002 Oct;4(5):377-80. Review.

PMID:
12217256
9.

Individualizing calcineurin inhibitor therapy in renal transplantation--current limitations and perspectives.

Press RR, de Fijter JW, Guchelaar HJ.

Curr Pharm Des. 2010;16(2):176-86. Review.

PMID:
20205663
10.

[Controversies about the use of calcineurin inhibitors in pediatric patients].

Dello Strologo L.

G Ital Nefrol. 2008 May-Jun;25(3):317-24. Review. Italian.

PMID:
18473303
11.

Calcineurin inhibitors in pediatric renal transplant recipients.

Filler G.

Paediatr Drugs. 2007;9(3):165-74. Review.

PMID:
17523697
12.

Which calcineurin inhibitor is preferred in renal transplantation: tacrolimus or cyclosporine?

Vanrenterghem YF.

Curr Opin Nephrol Hypertens. 1999 Nov;8(6):669-74. Review.

PMID:
10630811
13.

[Cytochrome P450 3A polymorphism and its importance in cyclosporine and tacrolimus therapy in transplanted patients].

Duricová J, Grundmann M.

Ceska Slov Farm. 2007 Oct;56(5):220-4. Review. Czech.

PMID:
18064802
14.

[Effect of genetic polymorphism on disposition of calcineurin inhibitors in solid organ transplantation].

Li D, Zhu L, Ye Q.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010 Sep;35(9):1018-22. doi: 10.3969/j.issn.1672-7347.2010.09.021. Review. Chinese.

15.

[Multiple actions of tacrolimus and cyclosporin A as specific inhibitors of calcineurin].

Tamura K.

Tanpakushitsu Kakusan Koso. 1998 Jun;43(8 Suppl):1118-30. Review. Japanese. No abstract available.

PMID:
9655970
16.

The CARI guidelines. Calcineurin inhibitors in renal transplantation: nephrotoxicity and calcineurin inhibitors.

Coates PT; Caring for Australians with Renal Impairment (CARI)..

Nephrology (Carlton). 2007 Feb;12 Suppl 1:S85-7. Review. No abstract available.

PMID:
17316286
17.
18.

Pharmacodynamic monitoring of calcineurin inhibition therapy: principles, performance, and perspectives.

van Rossum HH, de Fijter JW, van Pelt J.

Ther Drug Monit. 2010 Feb;32(1):3-10. doi: 10.1097/FTD.0b013e3181c0eecb. Review.

PMID:
20009796
19.

[Calcineurin inhibitor nephrotoxicity in renal allografts].

Takeda A, Morozumi K.

Nihon Jinzo Gakkai Shi. 2011;53(4):610-4. Review. Japanese. No abstract available.

PMID:
21688481
20.

Inhibitors of the calcineurin/NFAT pathway.

Martínez-Martínez S, Redondo JM.

Curr Med Chem. 2004 Apr;11(8):997-1007. Review.

PMID:
15078162

Supplemental Content

Support Center